Skip to main content

Table 2 ADRs of bDMARDs in patients with JIA, JSLE and JDM

From: Adverse drug reactions associated with treatment in patients with chronic rheumatic diseases in childhood: a retrospective real life review of a single center cohort

 

Medications

ETN

ADA

IFX

TCZ

ABA

RTX

TOTAL

Patients on MED

54

49

36

9

7

10

165

Patients on MED with ADR

10

6

11

2

1

30

Patients on MED with ADR(%)

18.5

12.2

30.5

22.2

10

18.2

Infections

1

1

2

Blood and lymphatic system disorders:

 - Thrombocytopenia

1

1

Nervous system disorders:

 - Headache/dizziness/discomfort

1

1

Eye disorders:

 - Uveitis

2

1

3

Gastrointestinal disorders:

 - Nausea/vomiting

2

3

1

6

 - Epigastric pain

1

1

Hepatobiliary disorders:

 -↑ liver enzymes

1

1

Skin and subcutaneous tissue disorders:

 - Atopic dermatitis

1

1

 - Psoriasis

1

1

 - Urticaria

3

1

4

Renal and urinary disorders:

 - Nephritis

1

1

 - Hematuria

1

1

General disorders and administration site conditions:

 - Anaphylaxis

2

2

 - Local reactions and pain

5

1

2

8

Total number of ADRs

11

8

11

2

1

33

  1. ADR - adverse drug reaction, JIA - juvenile idiopathic arthritis, JSLE - juvenile systemic lupus erythematosus, JDM - juvenile dermatomyositis, MED - Medication. Patients on MED- number of patients who used the medication. Patients on MED with ADR- number of patients who used the medication and experienced at least one adverse drug reaction. Patients on MED with ADR(%)- percentage of patients who used the medication and experienced at least one adverse drug reaction = N. P with ADR X 100/N.P on MED. ↑ liver enzymes - elevated liver enzymes. ETN - etanercept (median dose - 1.1 mg/kg/week and median length of treatment - 8.4 months). ADA - adalimumab (median dose - 0.8 mg/kg/dose every 15 days and median length of treatment - 11 months). IFX - infliximab (median dose - 5.4 mg/kg/dose every 8 weeks and median length of treatment - 8.4 months). TCZ - tocilizumab (median dose - 9.7 mg/kg/dose monthly and median length of treatment - 7.5 months). ABA - abatacept (median dose - 10 mg/kg/dose monthly and median length of treatment - 12 months). RTX - rituximab (median dose 1 g/dose twice monthly every 6 months)